MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel Central Nervous System (CNS) and pain therapies, announced that shareholders today authorized the Company to allocate up to 1.3 million shares to raise capital. “Newron is committed to bringing much needed new therapies to patients with CNS diseases,” said Stefan Weber, CEO of Newron. “With EU marketing authorization in place for Xadago® (safinamide) for Parkinson’s disease (PD) and the NDA accepted by the U.S. FDA, we are focused on advancing our programs for Rett syndrome, schizophrenia, treatment resistant PD and amyotrophic lateral sclerosis (ALS). The authorization for this share allocation enables us to raise funds to advance these clinical programs.”
Help employers find you! Check out all the jobs and post your resume.
